News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Clinical and Preclinical Results for Acetylon Pharmaceuticals' ACY-1215 for the Treatment of Multiple Myeloma Presented at the 54th Annual Meeting of the American Society of Hematology


12/11/2012 10:26:26 AM

BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today presented clinical and preclinical results for its selective histone deacetylase (HDAC) 6 inhibitor, ACY-1215, for the treatment of multiple myeloma (MM) at the 54th Annual Meeting of the American Society of Hematology (ASH) taking place in Atlanta, Georgia. Preliminary results from the Phase 1/2 study of ACY-1215 suggest that selective inhibition of HDAC6 with ACY-1215 in combination with bortezomib (VelcadeĀ®, Takeda Millennium Pharmaceuticals) and dexamethasone may provide a well-tolerated treatment option for relapsed or relapsed/refractory MM. In addition, preclinical results for ACY-1215 indicate a potential beneficial role of HDAC6 inhibition in MM-related bone disease. Together, these results show that selective HDAC6 inhibition through ACY-1215 may act favorably on both tumors and bone forming cells to benefit patients with MM.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES